Shanghai Fosun Pharmaceutical Unit Gets Drug Registration for Cancer Treatment

MT Newswires Live09-30

Shanghai Fosun Pharmaceutical (SHA:600196) unit Gismed (Wuhan) Pharmaceutical secured the drug registration approval for its oxaliplatin injection.

Oxaliplatin is mainly used in combination with 5-fluorouracil and folinic acid for the first-line treatment of metastatic colorectal cancer, according to a Sunday filing with the Shanghai bourse.

Shanghai Fosun Pharmaceutical has invested about 3.5 million yuan in research and development for oxaliplatin as of August.

Price (RMB): Â¥26.83, Change: Â¥+1.7, Percent Change: +6.68%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2471467128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-30 12:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2471467128","market":"us","top_or_hot":-1,"title":"Shanghai Fosun Pharmaceutical Unit Gets Drug Registration for Cancer Treatment","media":"MT Newswires Live","content":"<html><body><p> Shanghai Fosun Pharmaceutical (SHA:600196) unit Gismed (Wuhan) Pharmaceutical secured the drug registration approval for its oxaliplatin injection.</p><p>Oxaliplatin is mainly used in combination with 5-fluorouracil and folinic acid for the first-line treatment of metastatic colorectal cancer, according to a Sunday filing with the Shanghai bourse.</p><p>Shanghai Fosun Pharmaceutical has invested about 3.5 million yuan in research and development for oxaliplatin as of August.</p><p>Price (RMB): Â¥26.83, Change: Â¥+1.7, Percent Change: +6.68%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Fosun Pharmaceutical Unit Gets Drug Registration for Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Fosun Pharmaceutical Unit Gets Drug Registration for Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-30 12:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Fosun Pharmaceutical (SHA:600196) unit Gismed (Wuhan) Pharmaceutical secured the drug registration approval for its oxaliplatin injection.Oxaliplatin is mainly used in combination with 5-...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2471467128","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2471467128","pubTimestamp":1727670513,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Fosun Pharmaceutical (SHA:600196) unit Gismed (Wuhan) Pharmaceutical secured the drug registration approval for its oxaliplatin injection.Oxaliplatin is mainly used in combination with 5-fluo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0060":"抗癌","BK0196":"行业龙头","BK0012":"证金概念","BK0175":"白马股","BK0096":"民营医院","BK0028":"国家队","BK0188":"融资融券","00656":"复星国际","BK0187":"一线龙头","BK0239":"医药制造","BK0183":"MSCI概念"},"translate_title":"上海复星医药单位获癌症治疗药品注册","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9,"00656":1},"content_text":"Shanghai Fosun Pharmaceutical (SHA:600196) unit Gismed (Wuhan) Pharmaceutical secured the drug registration approval for its oxaliplatin injection.Oxaliplatin is mainly used in combination with 5-fluorouracil and folinic acid for the first-line treatment of metastatic colorectal cancer, according to a Sunday filing with the Shanghai bourse.Shanghai Fosun Pharmaceutical has invested about 3.5 million yuan in research and development for oxaliplatin as of August.Price (RMB): Â¥26.83, Change: Â¥+1.7, Percent Change: +6.68%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2471467128"}